Lung Cancer Trial, Recruiting NCT05375591 Sponsor: Royal Marsden NHS Foundation Trust Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT05375591
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been previously diagnosed with a solid organ cancer (a cancer forming a tumour in an organ, not a blood cancer) within the last 10 years, received treatment intended to cure or fully remove that cancer, and now have a new spot (nodule) detected on a chest CT scan
  • People whose previous cancer was confirmed either by a biopsy, or by a specialist medical team's agreement that it was cancer, and where the cancer was shown to have gone away or gone into remission after treatment
  • People whose previous cancer was treated with the intention to cure it — through surgery, radiation therapy, chemotherapy, a combination of these, or similar aggressive treatments
  • People where it is already known what the new lung nodule is — either confirmed as harmless (benign) and stable or gone away over 2 years of scans, or confirmed as a new or returning cancer through scans, specialist team review, or biopsy
  • People whose chest CT scan images have a slice thickness (level of detail) of 2.5mm or less
  • People whose lung nodule measures 5mm or larger in size

Who may not be able to join:

  • People whose CT scan images are more than 10 years old
  • People whose cancer is a blood cancer (such as leukaemia) rather than a solid tumour
  • People whose original cancer came back in only a small number of spots (called oligometastatic recurrence) and those spots were also treated with curative-intent treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Richard Lee, The Royal Marsden Hospitals NHS Trust

Phone: 020 7808 2603

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Royal Marsden NHS Foundation Trust
Registry
ClinicalTrials.gov
Start date
13 October 2021
Est. completion
1 November 2022

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Development of a CT-thorax based radiomics ML classifier model to predict cancer risk in new lung nodules after previous radically treated cancer.; Development of the CT-thorax based ML classifier model to predict whether a new malignant nodule represents metastatic lung disease (new cancer vs previous cancer recurrence) or a new primary lung malignancy.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov